Financière de Tubize SA

Financière de Tubize SA is a holding company and the reference shareholder of UCB, a leading global biopharmaceutical company based in Belgium. It owns approximately 36.27% of UCB, uniting family shareholders descended from founder Emmanuel Janssen with others sharing a long-term vision for the company's growth. The company's primary function is to support UCB's development as a committed stakeholder, fostering a rich biopharma ecosystem worldwide to enhance value creation for patients. UCB specializes in innovative treatments for neurology and immunology disorders, with key products including CIMZIA for rheumatoid arthritis and Crohn’s disease, Keppra and Vimpat for epilepsy, Zyrtec antihistamine, BIMZELX for plaque psoriasis, FINTEPLA for rare epilepsy syndromes, and RYSTIGGO and ZILBRYSQ for myasthenia gravis. Historically, Financière de Tubize has deepened its UCB stake since first investing decades ago, peaking at 40% in 2002, and participated in capital increases for acquisitions like Celltech, Schwarz Pharma, Ra Pharmaceuticals, and Zogenix. Operating in the healthcare sector with a focus on biotechnology, it plays a pivotal role in sustaining UCB's advancements in genetics, biomarkers, and human biology, primarily generating revenue in the United States followed by Europe. With around 250 employees, Financière de Tubize SA underscores stability in the biopharma investment landscape.